ezyVet vs Incyte
Side-by-side comparison of AI visibility scores, market position, and capabilities
Cloud Veterinary Practice Management & Client Engagement
Cloud vet practice management acquired by IDEXX; Auckland New Zealand; 5,000+ clinics in US, Australia, NZ, and UK; covers patient check-in through invoicing and end-of-day reconciliation.
About
ezyVet is a cloud-based veterinary practice management and client engagement platform that provides veterinary clinics with patient records, scheduling, invoicing, billing, client communication, and analytics in a fully browser-based system, headquartered in Auckland, New Zealand and acquired by IDEXX Laboratories — the global veterinary diagnostics leader — in 2021 to extend IDEXX's software platform capabilities alongside its diagnostic products. ezyVet serves more than 5,000 veterinary clinics globally with particular strength in the United States, Australia, New Zealand, and the United Kingdom.\n\nezyVet's platform provides a comprehensive clinical workflow covering patient check-in, consultation and treatment planning, prescription management, invoicing, and end-of-day reconciliation. The two-way client communication features include automated appointment reminders via SMS and email, post-visit summaries, and a client portal where pet owners can access records and request appointments. Deep integration with IDEXX's diagnostic products — including in-clinic analyzers, reference laboratory services, and imaging systems — allows results to flow directly into patient records, providing a significant competitive advantage now that IDEXX owns the platform.\n\nAs an IDEXX-owned platform, ezyVet benefits from IDEXX's global distribution network, integration with IDEXX's full diagnostics portfolio, and the ability to bundle software with diagnostic equipment and service agreements. ezyVet competes with Provet Cloud, Vetspire, Digitail, and the legacy IDEXX Cornerstone platform in the veterinary software market. IDEXX's ownership creates both an advantage (deep diagnostics integration) and a competitive consideration for clinics that use non-IDEXX diagnostic products.
Wilmington DE oncology/inflammation biopharma (NASDAQ: INCY) ~$3.9B FY2024 revenue; Jakafi $2.7B myelofibrosis franchise, Opzelura topical JAK inhibitor, Novartis Jakavi royalties competing with BMS and Pfizer.
About
Incyte Corporation is a Wilmington, Delaware-based biopharmaceutical company — publicly traded on the NASDAQ (NASDAQ: INCY) as an S&P 500 Health Care component — focused on oncology and inflammation, best known for Jakafi (ruxolitinib), the first FDA-approved therapy for myelofibrosis and polycythemia vera — rare blood cancers driven by JAK kinase pathway mutations — and the topical ruxolitinib cream Opzelura (for atopic dermatitis and vitiligo). In fiscal year 2024, Incyte reported revenues of approximately $3.9 billion, with Jakafi net product revenues of approximately $2.7 billion (the primary revenue driver) and collaboration revenues from Novartis (which pays Incyte royalties on Jakavi — the ex-US brand name for ruxolitinib — representing a significant royalty income stream from international myelofibrosis and polycythemia vera markets). CEO Hervé Hoppenot's strategy of building a diversified hematology-oncology pipeline beyond ruxolitinib has progressed through the development of axatilimab (anti-CSF-1R monoclonal antibody for chronic graft-versus-host disease — FDA-approved 2024 as Niktimvo) and povorcitinib (JAK inhibitor for prurigo nodularis and hidradenitis suppurativa — phase 3 trials in dermatology). Incyte's JAK inhibitor chemistry platform (ruxolitinib — Jakafi/Opzelura/Jakavi, parsaclisib, itacitinib, tofacitinib licensed from Pfizer collaboration) provides a productive medicinal chemistry foundation for developing next-generation kinase inhibitors with more selective pharmacology profiles.
AI Visibility Head-to-Head
Key Details
Capabilities & Ecosystem
Capabilities
Integrations
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.